Despite the development of treatment modalities for OSCC such as surgical extraction, chemoradiotherapy, or epidermal growth factor receptor (EGFR)-targeting therapies in the last three decades, the prognosis of OSCC is still poor due to resistance to treatment modalities and cancer recurrence with a five-year survival rate of <50% [2]. This evidence concerns the gene EGFR and cancer.